首页> 美国卫生研究院文献>Molecular Neurodegeneration >Altered synaptic structure in the hippocampus in a mouse model of Alzheimer’s disease with soluble amyloid-β oligomers and no plaque pathology
【2h】

Altered synaptic structure in the hippocampus in a mouse model of Alzheimer’s disease with soluble amyloid-β oligomers and no plaque pathology

机译:阿尔茨海默氏病小鼠模型中海马突触结构的改变该模型具有可溶性淀粉样β寡聚体且无斑块病理

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundMounting evidence suggests that soluble oligomers of amyloid-β (oAβ) represent the pertinent synaptotoxic form of Aβ in sporadic Alzheimer’s disease (AD); however, the mechanistic links between oAβ and synaptic degeneration remain elusive. Most in vivo experiments to date have been limited to examining the toxicity of oAβ in mouse models that also possess insoluble fibrillar Aβ (fAβ), and data generated from these models can lead to ambiguous interpretations. Our goal in the present study was to examine the effects of soluble oAβ on neuronal and synaptic structure in the amyloid precursor protein (APP) E693Q (“Dutch”) mouse model of AD, which develops intraneuronal accumulation of soluble oAβ with no detectable plaques in AD-relevant brain regions. We performed quantitative analyses of neuronal pathology, including dendrite morphology, spine density, and synapse ultrastructure in individual hippocampal CA1 neurons.
机译:背景研究表明,淀粉样蛋白-β(oAβ)的可溶性低聚物代表散发性阿尔茨海默病(AD)中相关的Aβ突触毒性形式;然而,oAβ和突触变性之间的机制联系仍然难以捉摸。迄今为止,大多数体内实验仅限于在还具有不溶性纤维状Aβ(fAβ)的小鼠模型中检查oAβ的毒性,并且从这些模型生成的数据可能导致模棱两可的解释。我们在本研究中的目标是检查可溶oAβ对AD的淀粉样前体蛋白(APP)E693Q(“ Dutch”)小鼠模型中神经元和突触结构的影响,该模型可在神经元内形成可溶oAβ的神经内蓄积,而在小鼠体内未检测到斑块。与AD相关的大脑区域。我们对神经元病理进行了定量分析,包括单个海马CA1神经元的树突形态,脊柱密度和突触超微结构。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号